Table 6.
Comprehensive evaluation based on 123I-mIBG scintigraphy.
| Target lesion | Non-target lesion | New lesion | CE |
|---|---|---|---|
| CR | CR | No | CR |
| CR | non-CR/non-PD | No | PR |
| CR | NE | No | PR |
| PR | non-CR/non-PD or NE | No | PR |
| SD | non-CR/non-PD or NE | No | SD |
| NE | Non-PD | No | NE |
| PD | — | — | PD |
| — | PD | — | PD |
| — | — | Yes | PD |
| — | CR | No | CR |
| — | non-CR/non-PD | No | non-CR/non-PD |
| — | NE | No | NE |
| — | PD | — | PD |
| — | — | Yes | PD |
mIBG: meta-iodobenzylguanidine; CR: complete response; PR: partial response; NE: not evaluated; CE: comprehensive evaluation; SD: stable disease; PD: progression disease.